TY - JOUR AU - Ocana, A. AU - Pandiella, A. PY - 2017 DA - 2017// TI - Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.14731 DO - 10.18632/oncotarget.14731 ID - Ocana2017 ER - TY - JOUR AU - Ocana, A. AU - Pandiella, A. PY - 2008 DA - 2008// TI - Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1630 DO - 10.1158/1078-0432.CCR-07-1630 ID - Ocana2008 ER - TY - JOUR AU - Filippakopoulos, P. AU - Qi, J. AU - Picaud, S. PY - 2010 DA - 2010// TI - Selective inhibition of BET bromodomains JO - Nature VL - 468 UR - https://doi.org/10.1038/nature09504 DO - 10.1038/nature09504 ID - Filippakopoulos2010 ER - TY - JOUR AU - Ocana, A. AU - Nieto-Jimenez, C. AU - Pandiella, A. PY - 2017 DA - 2017// TI - BET inhibitors as novel therapeutic agents in breast cancer JO - Oncotarget VL - 8 ID - Ocana2017 ER - TY - JOUR AU - Perez-Pena, J. AU - Serrano-Heras, G. AU - Montero, J. C. PY - 2016 DA - 2016// TI - In silico analysis guides selection of BET inhibitors for triple-negative breast Cancer treatment JO - Mol Cancer Ther VL - 15 UR - https://doi.org/10.1158/1535-7163.MCT-16-0004 DO - 10.1158/1535-7163.MCT-16-0004 ID - Perez-Pena2016 ER - TY - JOUR AU - Shi, J. u. n. w. e. i. AU - Vakoc, C. h. r. i. s. t. o. p. h. e. r.  . R. PY - 2014 DA - 2014// TI - The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition JO - Molecular Cell VL - 54 UR - https://doi.org/10.1016/j.molcel.2014.05.016 DO - 10.1016/j.molcel.2014.05.016 ID - Shi2014 ER - TY - JOUR AU - Shu, S. AU - Lin, C. Y. AU - He, H. H. PY - 2016 DA - 2016// TI - Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer JO - Nature VL - 529 UR - https://doi.org/10.1038/nature16508 DO - 10.1038/nature16508 ID - Shu2016 ER - TY - JOUR AU - Stratikopoulos, E. E. AU - Dendy, M. AU - Szabolcs, M. PY - 2015 DA - 2015// TI - Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.05.006 DO - 10.1016/j.ccell.2015.05.006 ID - Stratikopoulos2015 ER - TY - JOUR AU - Nieto-Jimenez, C. AU - Alcaraz-Sanabria, A. AU - Perez-Pena, J. PY - 2017 DA - 2017// TI - Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.14465 DO - 10.18632/oncotarget.14465 ID - Nieto-Jimenez2017 ER - TY - JOUR AU - Ma, Y. AU - Wang, L. AU - Neitzel, L. R. PY - 2017 DA - 2017// TI - The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal Cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0453 DO - 10.1158/1078-0432.CCR-16-0453 ID - Ma2017 ER - TY - JOUR AU - Jang, J. E. AU - Eom, J. I. AU - Jeung, H. K. PY - 2017 DA - 2017// TI - AMPK-ULK1-mediated autophagy confers resistance to BET inhibitor JQ1 in acute myeloid leukemia stem cells JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1903 DO - 10.1158/1078-0432.CCR-16-1903 ID - Jang2017 ER - TY - JOUR AU - Fong, C. Y. AU - Gilan, O. AU - Lam, E. Y. PY - 2015 DA - 2015// TI - BET inhibitor resistance emerges from leukaemia stem cells JO - Nature VL - 525 UR - https://doi.org/10.1038/nature14888 DO - 10.1038/nature14888 ID - Fong2015 ER - TY - JOUR AU - Wang, P. AU - Zhou, J. PY - 2018 DA - 2018// TI - Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery JO - Curr Top Med Chem VL - 18 UR - https://doi.org/10.2174/1568026618666181010101922 DO - 10.2174/1568026618666181010101922 ID - Wang2018 ER - TY - JOUR AU - Zengerle, M. AU - Chan, K. H. AU - Ciulli, A. PY - 2015 DA - 2015// TI - Selective small molecule induced degradation of the BET Bromodomain protein BRD4 JO - ACS Chem Biol VL - 10 UR - https://doi.org/10.1021/acschembio.5b00216 DO - 10.1021/acschembio.5b00216 ID - Zengerle2015 ER - TY - JOUR AU - Lu, J. AU - Qian, Y. AU - Altieri, M. PY - 2015 DA - 2015// TI - Hijacking the E3 ubiquitin ligase Cereblon to efficiently target BRD4 JO - Chem Biol VL - 22 UR - https://doi.org/10.1016/j.chembiol.2015.05.009 DO - 10.1016/j.chembiol.2015.05.009 ID - Lu2015 ER - TY - JOUR AU - Sun, B. AU - Fiskus, W. AU - Qian, Y. PY - 2018 DA - 2018// TI - BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells JO - Leukemia VL - 32 UR - https://doi.org/10.1038/leu.2017.207 DO - 10.1038/leu.2017.207 ID - Sun2018 ER - TY - JOUR AU - Ocana, A. AU - Garcia-Alonso, S. AU - Amir, E. AU - Pandiella, A. PY - 2018 DA - 2018// TI - Refining early Antitumoral drug development JO - Trends Pharmacol Sci VL - 39 UR - https://doi.org/10.1016/j.tips.2018.09.003 DO - 10.1016/j.tips.2018.09.003 ID - Ocana2018 ER - TY - JOUR AU - Saenz, D. T. AU - Fiskus, W. AU - Qian, Y. PY - 2017 DA - 2017// TI - Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.393 DO - 10.1038/leu.2016.393 ID - Saenz2017 ER - TY - JOUR AU - Zhang, X. i. a. o. h. u. i. AU - Lee, H. a. n. s. C. AU - Shirazi, F. a. z. a. l. AU - Baladandayuthapani, V. e. e. r. a. b. h. a. d. r. a. n. AU - Lin, H. e. a. t. h. e. r. AU - Kuiatse, I. s. e. r. e. AU - Wang, H. u. a. AU - Jones, R. i. c. h. a. r. d. J. AU - Berkova, Z. u. z. a. n. a. AU - Singh, R. a. m. K. u. m. a. r. AU - Lu, J. i. n. g. AU - Qian, Y. i. m. i. n. AU - Raina, K. a. n. a. k. AU - Coleman, K. e. v. i. n. G. AU - Crews, C. r. a. i. g. M. AU - Li, B. i. n. g. z. o. n. g. AU - Wang, H. u. i. h. a. n. AU - Hailemichael, Y. a. r. e. d. AU - Thomas, S. h. e. e. b. a. K. AU - Wang, Z. h. i. q. i. a. n. g. AU - Davis, R. E. r. i. c. AU - Orlowski, R. o. b. e. r. t. Z. PY - 2018 DA - 2018// TI - Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma JO - Leukemia VL - 32 UR - https://doi.org/10.1038/s41375-018-0044-x DO - 10.1038/s41375-018-0044-x ID - Zhang2018 ER -